RAPIDNSTEMI - Revascularisation in ACS Patients: Immediate versus Delayed Intervention A study assessing the impact of very early intervention on outcomes in NSTEMI-ACS patients

A large clinical trial is testing whether heart attack patients with a less severe form of the condition should receive emergency artery-opening treatment immediately, rather than waiting the standard 72 hours. Around 20% of patients with non-ST-elevation myocardial infarction (NSTEMI) suffer a major cardiac event—such as a second heart attack, heart failure, or death—within a year. Current guidelines recommend performing percutaneous coronary intervention (PCI) during the hospital stay, but the optimal timing remains uncertain. This trial, called RAPIDNSTEMI, will randomise 2,314 patients to either immediate PCI or the current standard of care (PCI within 72 hours). Using high-sensitivity troponin tests to quickly confirm the diagnosis, researchers aim to see if very early intervention reduces the 12-month composite rate of death, new heart attack, or heart failure readmission. If the immediate approach proves superior, it could change national and international guidelines, shifting how hospitals triage and treat a common cardiac emergency. That would directly affect patient outcomes and healthcare service planning—no fundamental science here, just a pragmatic test of a faster treatment pathway.